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Summary 
Cells, tissues and organs undergo phenotypic changes and deteriorate as they age. Cell 
growth arrest and hyporesponsiveness to extrinsic stimuli are all hallmarks of senescent 
cells. Most such external stimuli received by a cell are processed by two different cell 
membrane systems: receptor tyrosine kinases (RTKs) and G protein-coupled receptors 
(GPCRs). GPCRs form the largest gene family in the human genome and they are 
involved in most relevant physiological functions. Given the changes observed in the 
expression and activity of GPCRs during aging, it is possible that these receptors are 
directly involved in aging and certain age-related pathologies. On the other hand, both 
GPCRs and G proteins are associated with the plasma membrane and since lipid-protein 
interactions regulate their activity, they can both be considered to be sensitive to the 
lipid environment. Changes in membrane lipid composition and structure have been 
described in aged cells and furthermore, these membrane changes have been associated 
with alterations in GPCR mediated signaling in some of the main health disorders in 
elderly subjects. Although senescence could be considered a physiologic process, not all 
aging humans develop the same health disorders. Here, we review the involvement of 
GPCRs and their lipid environment in the development of the major human pathologies 
associated with aging such as cancer, neurodegenerative disorders and cardiovascular 
pathologies. 
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Organisms, cells and even proteins are subject to time-dependent degenerative 
processes. As such, aging is characterized by the accumulation of adverse changes in 
cells over time, which augments the risk of disease, and the breakdown of homeostatic 
control and death [1]. Moreover, the process of aging is also manifested as senescence, 
involving the deterioration of certain functions at the cell and tissue level as well as that 
of the whole organism. Since aging plays an important role in many biological 
processes including development, tumorigenesis and death, many attempts have been 
made to understand the fundamental features underlying aging [2]. 
Cell growth arrest and hyporesponsiveness to extrinsic stimuli are hallmarks of 
senescent cells [3, 4]. The influences of the external stimuli involved are mainly 
mediated by two different systems at the level of the cell membrane. One of these 
involves receptor tyrosine kinases (RTKs) that bind growth factors and activate signal 
cascades through the phosphorylation of tyrosine residues in the receptor. The other 
depends on G protein-coupled receptors (GPCRs) that make up approximately 5% of 
the genes in eukaryotic organisms [5, 6]. GPCRs constitute the main family of receptors 
for neurotransmitters, hormones and neuromodulators. Upon agonist binding, they 
undergo conformational changes that result in the activation of heterotrimeric G 
proteins and that modulate the activity of effector proteins (e.g. adenylyl cyclase [AC], 
phospholipase C [PLC], A2 [PLA2], guanylyl cyclase [GC] and some ion channels). 
These effectors regulate the cytosolic levels of second messengers, which in turn 
influence the activity of third messengers and so on. Finally, a single signaling event 
may originate short-, medium-, and long-term responses that regulate a cell’s activity 
and its responses to environmental conditions through molecular events such as the 
regulation of gene expression, cross-talk and other complex phenomena. After 
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remaining active for a time, GPCRs are phosphorylated by G-protein receptor kinases 
(GRK) and other kinases, extinguishing the receptor’s activity [7, 8]. 
Age-dependent changes can occur at several different levels, from the ligand-
receptor interaction at the cell surface to the various downstream signaling cascades 
with which these receptors interact. GPCRs form the largest gene family in the human 
genome and they are involved in most relevant physiological functions. This fact and 
the changes observed in the expression and activity of GPCRs during aging, indicate 
that these receptors may be involved in aging and associated pathologies [4]. 
Membrane lipids have recently been shown to influence GPCR-associated 
signaling [9, 10] and aging [11, 12]. Some specific properties of cell membranes (i.e., 
fluidity, nonlamellar phase propensity, surface packing, thickness, surface charge, etc.) 
are critical for many membrane events, such as receptor and G protein localization, 
activity and sorting of G protein subunits upon activation, etc. Moreover, the structure 
and lipid composition of the membrane regulates the function and localization of several 
membrane signaling proteins [10, 13-17]. Changes in membrane lipid composition are 
frequently accompanied by alterations in the fluidity, lipid structure, and functionality 
of the membrane [18, 19]. Accordingly, modifications in the lipid composition and the 
physical properties of cell membranes, in cell signaling and in gene expression have 
been identified in different tissues from elderly subjects, including the brain [18, 20-23]. 
Interestingly, membrane fatty acid composition is an important determinant of the 
lifespan of different species [12]. In this context, alterations in membrane lipids can 
induce changes in the activity and localization of GPCRs in aged cells. Therefore, 
interventions that involve manipulating dietary lipids and lipid metabolism, including 
changes in diet or the administration of cholesterol-modifying agents and antioxidants, 
show great promise in slowing or possibly averting the development of some human 
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diseases associated with aging including some types of cancer, Alzheimer´s Disease 
(AD), hypertension and other cardiovascular disorders [24-32]. 
Although senescence could be considered a physiological process, not all aging 
individuals develop the same health disorders. Here we shall review the involvement of 
GPCRs in the development of major human pathologies in aging, such as cancer, 
cardiovascular and neurodegenerative disorders (mainly AD). We shall focus on the 
alterations of membrane lipid composition and structure associated with these 
pathologies, its influence on GPCR signaling, and the beneficial effects of some fatty 
acid-rich diets on healthy aging. 
GPCRs and aging in cancers 
In general, there is a positive correlation between age and the incidence of 
cancer, in particular in breast, lung, prostate, and colon cancers [33, 34]. Cancers 
originate through defects in the control of cell proliferation, usually associated with 
mutations in proto-oncogenes, tumor suppressors and other signaling proteins. 
Obviously, the probability that a cell might bear a mutation increases with age and 
indeed, many cancers require the accumulation of multiple mutations. For instance, p53 
induces apoptosis of cells with genetic alterations that cannot be repaired and mutations 
in p53 have been observed in about 50% of all human tumors. However, p53 alone does 
not induce uncontrolled cell proliferation, but rather the deficiency in p53 function 
allows a cell with mutation in genes involved in proliferation to divide continuously. It 
is therefore clear that in most cancers, the probability of developing a tumor increases 
with age (Fig. 1) [35]. Nevertheless, it should be noted that exceptions to this rule do 
exist, as is the case for pilocytic astrocytoma (Fig. 1). 
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With respect to GPCRs and their related proteins, the role they fulfill in the 
control of cell proliferation is closely associated with their involvement in the 
development of certain cancers [36-39]. Indeed, changes in the expression and function 
of these receptors may result in cellular transformation (see the review by Gutkind et al. 
in this issue). Recent studies have demonstrated that GPCRs are implicated in 
tumorigenesis and metastasis [40]. Changes in the expression of GPCRs or mutations in 
the genes encoding these receptors have been observed in some cancers, indicating that 
certain GPCRs can behave as potent agonist-dependent oncogenes [41, 42]. One 
example of a growth-stimulatory role of GPCRs can be seen in small cell lung 
carcinoma (SCLC) cells, where neuropeptides like gastrin-releasing peptide (GRP), 
galanin, vasopressin, etc., activate GPCRs [41, 43-45]. SCLC constitutes approximately 
25% of all lung cancers and it is characterized by a very low 5-year survival rate, 
despite the initial sensitivity that it displays to radio- and chemotherapy. In SCLC, 
neuropeptides activate GPCRs that are coupled to more than one G protein family (i.e., 
Gq/11 and G12/13 [41]) thereby stimulating phospholipase C [46] and ERK [47] 
activity, which promotes cell proliferation. Thus, through an autocrine feedback on 
GPCRs neuropeptides represent the principal mitogens of SCLC [44] and indeed, 
neuropeptide growth factor antagonists have been developed to treat SCLC [48]. 
The detection of activating mutations of the human thyrotropin (TSH) receptor 
in some types of thyroid carcinomas established a causal link between GPCRs and 
autonomous cell growth [49]. The human TSH receptor has an exceptionally broad 
profile of G protein coupling and it is able to interact with members of all four G protein 
families, Gs, Gi, Gq and G12 [50, 51]. The cAMP regulatory cascade has also been 
implicated in the control of growth and differentiation, whereas calcium and 
diacylglycerol (Gq/phospholipase C-β activation) are thought to stimulate iodination and 
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thyroid hormone synthesis [52]. In approximately 30% of hyperfuctional thyroid 
adenomas, GTPase-inhibiting mutations in Gαs are responsible for the increased cAMP 
synthesis characteristic of this tumor. Similarly, mutations in the THS receptor 
constitutively activate its ability to stimulate G- and AC-catalyzed cAMP synthesis [53-
55]. Moreover, alterations in the desensitization of GPCRs in the thyroid gland play a 
crucial role in thyroid pathologies [56]. In differentiated thyroid carcinomas (where 
TSH acts as a mitogenic agent), changes in the levels of GRK5 are correlated with a 
decrease in the desensitization of the TSH receptor that provokes an increase in cAMP 
synthesis [57]. Likewise, an increase in GRK3 expression was detected in 
hyperfunctional thyroid nodules (HTNs), suggesting a potential role for this GRK as a 
negative feedback regulator for the constitutively activated cAMP pathway in these 
structures [56]. Similar alterations in GPCR and GRK activation and/or expression are 
associated with the development of breast cancer [58-61], with neoplastic 
transformation in the prostate [62-65] and in human colon cancer [66]. All these cancers 
become more prevalent with age, most probably due to their dependence on the 
accumulation of mutations. 
Taken together, these results show that mutations in GPCRs, G proteins, their 
effectors and GRKs are all involved in the etiology of several human cancers, 
particularly those involving hormone dependence. Hence, it would appear that these 
proteins might be relevant pharmacological targets for selective strategies aimed at 
antagonizing distinct mitogenic stimuli. Tumor growth and metastasis are both 
processes that are affected by changes in membrane lipid composition and accordingly, 
lipid alterations might be involved in the development of some types of cancer. In this 
context, a wide variety of molecular entities that control cell proliferation and survival 
are membrane-associated proteins. Indeed, alterations in the levels of certain membrane 
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lipids have been observed in cell membranes from patients with cancer and from cancer 
cells that are resistant to chemotherapy [13, 67, 68]. Interestingly, compounds that 
modulate the membrane lipid structure (e.g. fatty acids) influence the cellular 
localization and activity of important membrane-associated signal transduction proteins 
[10, 14, 15, 69], thereby producing molecular and cellular alterations that affect cell 
signaling and division [70, 71]. Thus, it is not surprising that the activity of various 
anticancer drugs is associated with their ability to alter membrane lipid composition, 
thereby affecting membrane lipid structure. Accordingly, the possibility of using lipids 
as targets to overcome anticancer drug resistance has recently been highlighted [67, 72]. 
GPCRs and aging in the brain under normal conditions and in association with 
neurodegenerative disorders 
A variety of age-related alterations in GPCRs have been observed in neuronal 
signaling systems [73]. While age-associated changes appear to be variable and 
dependent on the specific brain region, the expression of most GPCRs and G proteins 
decreases in the human brain with age [74-77]. Indeed, like most brain neurotransmitter 
receptors, the density of β-adrenoceptors decreases with age in the human brain [78]. 
This decline is largely associated with the degeneration of noradrenergic nerve 
terminals [79] and it is mainly due to the loss of high-affinity receptors [76]. The human 
brain contains all three subtypes of α2-adrenoceptors identified by molecular cloning 
(α2A, α2B, and α2C), the α2A-adrenoceptor being the most abundant in the frontal cortex 
[75]. The density of α2A-adrenoceptors and associated regulatory G proteins has also 
been shown to decrease with aging in the human brain [74, 75, 80]. The concomitant 
decrease in the density of α2A- and β-adrenoceptors in the frontal cortex suggests a 
relationship between both these GPCRs [76]. Both adrenoceptors belong to a large 
family of membrane receptors that regulates AC activity through Gαs and Gαi proteins 
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[81-83]. Some studies reveal a decline of various Gα proteins and their signal 
transduction cascades within the aging human brain [75, 76, 84, 85]. This coordinated 
decrease in the density of β- and α2A-adrenoceptors indicates the existence of a 
relationship between these receptors and their signaling proteins [76]. Furthermore, the 
muscarinic acetyl choline (ACh) receptor (mAChR) system loses its sensitivity to ACh 
stimulation both during aging and in AD [73, 86, 87]. In contrast to most receptors and 
signaling proteins, the presence of other receptors and signaling-related proteins may 
also increase with age, as seen for the imidazoline receptors and monoamine oxidase 
[88, 89]. This would indicate that the loss of such elements is not unspecific. 
AD is currently the commonest cause of senile dementia among humans over 65, 
and it is characterized by a progressive cognitive decline coupled defined by the loss of 
memory, cognitive abilities, and even of personality. These changes are due to the 
progressive dysfunction and death of neurons responsible for learning and memory. AD 
is characterized by a variety of pathological features, such as the extracellular senile 
plaques formed by amyloid β peptides, the appearance of intracellular neurofibrillary 
tangles consisting of twisted filaments of hyperphosphorylated tau protein, the loss of 
neuronal subpopulations and cholinergic fibers, and brain atrophy [90-94]. The amyloid 
β precursor protein (APP) is a membrane protein and the proteolytic fragments 
generated during AD form deposits on the extracellular face of the cell membrane. It 
has recently been demonstrated that a gradual decline in the cellular processing and 
maturation of APP is one of the main pathogenic mechanisms for familial and age-
associated AD [95]. GPCRs have recently been implicated in APP processing. In this 
context, the somatostatin receptor has been identified as a modulator that decreases 
amyloid β levels by increasing brain neprilysin activity [96], a rate-limiting peptidase 
involved in the physiological degradation of amyloid β in the brain [97]. Thus, reduced 
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neprilysin activity contributes to amyloid β accumulation and consequently, to AD 
development. There is evidence that neprilysin is down-regulated in the hippocampus 
and cerebral cortex with aging [98] and from an early stage of AD development [99-
101], supporting the association of neprilysin activity with the etiology and 
pathogenesis of AD. Therefore, the up-regulation of neprilysin through the 
somatostatin-activated GPCR signaling pathway may represent a promising target for 
AD therapeutic and preventative strategies [102]. 
Postsynaptic M1 AChRs are found at high density in the neocortex and 
hippocampus, where they mediate cholinergic neurotransmission in a variety of CNS 
functions including learning and memory [103]. Of the neurotransmitter pathologies 
associated with AD, cholinergic dysfunction occurs early in the disease process [104] 
and it is thought to underlie much of the characteristic cognitive and neuropsychiatric 
symptoms [105-107]. In addition, the ability of the mAChR to form high affinity 
agonist-binding complexes with G proteins was impaired in AD [108] and 
phosphoinositide hydrolysis, as well as phospholipase C and PKC activity was reduced 
[104, 109, 110]. Recently, the reduction in M1 AChR/G-protein coupling has been 
related to the severity of cognitive symptoms in the neocortex of AD patients. Thus, that 
impairment of M1 AChR-mediated signaling through uncoupling of its G protein may 
be a neurochemical cause of cognitive decline in AD [111]. Potential mechanisms for 
the loss of GPCR-G protein coupling in AD may be aberrant phosphorylation or 
dephosphorylation of these receptors, which in turn may alter their association with G 
proteins and/or the levels or activity of G proteins (e.g., loss of GTPase activity). 
Accordingly, both G protein subunit concentrations and activity are altered in different 
regions of the AD brain, thereby modifying GPCR-mediated AC signaling. In fact, it 
has been reported that inhibition of AC mediated by Gs protein but not Gi is disrupted 
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in various brain regions in AD patients [112-116]. Furthermore, the interactions 
between the β1-adrenoceptor and Gs protein are disrupted in the temporal cortex in AD 
[117] and β-adrenoceptor-stimulated cAMP production is reduced in fibroblasts from 
sporadic AD cases [118]. Finally, a deficit in cytosolic PKA has been associated with 
the accumulation of neurofibrillary changes and amyloid β deposits in the AD brain 
[119]. 
The fatty acid composition of neural tissue plays an important role in 
neurodevelopment, changing significantly during periods of rapid brain growth [120]. 
Indeed, neural tissue has the highest lipid content after adipose tissue. The levels of 
polyunsaturated (PUFA) and monounsaturated fatty acids (MUFA) in the cerebral 
cortex change from early childhood through late adulthood [121], and some studies 
suggest that neurocognitive function may be related to the fatty acid composition of 
developing brain [122-124]. Accordingly, alterations in brain fatty acid composition 
have been reported in several diseases associated with neurodegenerative disorders 
[125, 126]. Neurodegeneration in AD is accompanied by lipid alterations, such as 
changes in the phosphocholine-containing lipids in cerebrospinal fluid [127], and in the 
levels of phospholipids and fatty acid in blood plasma and brain membranes [128, 129]. 
Furthermore, several aspects related to the etiology of AD are associated with 
alterations of lipid membrane composition and structure. On the one hand, APP is a 
membrane protein and as mentioned, the resulting proteolytic fragment forms deposits 
on the extracellular side of the lipid bilayer. Recent results demonstrate that age-
dependent membrane modifications are associated with alteration in the distribution of 
presenilin-1 and a beta-APP-cleaving enzyme, very likely affecting APP processing and 
leading to its accumulation [95]. On the other hand, some membrane alterations could in 
part explain the cognitive deficits reported in mice with neurodegenerative disorders 
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[19, 130-132], as well as the impaired neurotransmitter-associated signaling observed in 
AD and aging [132, 133]. These specific alterations in membrane lipids have led to 
studies on the effects of phospholipid and fatty acid supplementation on the mental 
status of patients with AD and in animal models of aging [28, 29, 134, 135]. Diets rich 
in carbohydrate [136], particularly those with a high glycemic index and those low in 
essential fatty acids (particularly ω-3 long-chain PUFAs) increase the risk of developing 
AD [137-140]. Likewise, the risk of AD may be increased through altered lipid 
metabolism and neuronal membrane lipid composition that may lead to changes in 
neurotransmission, antioxidant defenses, inflammatory responses, cerebral blood flow, 
and cognitive function [20, 27, 31, 141, 142]. It would be particular interesting to 
determine the beneficial effects of anti-oxidants and anti-inflammatory ω-3 PUFAs 
[27]. Similarly, essential components of the Mediterranean diet protect against age-
related cognitive decline [143, 144], as well as protecting against atherosclerosis in an 
animal model of neurodegeneration [145]. Furthermore, there is evidence that this diet 
also benefits inflammatory and cardiovascular parameters [25]. 
GPCRs and aging in cardiovascular disorders 
Adrenergic receptors are important regulators of cardiovascular physiology. The 
β-adrenergic receptor is activated by both noradrenaline and adrenaline, and it is a target 
for many medications prescribed to the elderly to treat hypertension, angina, post-
myocardial infarction risk, congestive heart failure, glaucoma, tremor, and arrhythmias 
[146]. The β-adrenergic receptor also exhibits age-related change in its activity in the 
cardiovascular system. 
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In the heart 
Human aging is associated with an increase in the activity of the sympathetic 
nervous system and with a decrease of cardiac neuronal uptake of catecholamines [147-
150]. In this situation, the cardiac adrenoceptors are exposed to chronic stimulation and 
hence, desensitization of cardiac β-adrenoceptors could be expected with age (for a 
review see [151]). Numerous studies in animals show that the cardiac responses 
mediated by the β-adrenoceptor diminish with age. Although such changes in the 
density of the β-adrenoceptor in the myocardium with age are not consistent (decrease, 
increase and no changes have been reported), impaired coupling of the β-adrenoceptor 
to the Gs protein and to the catalytic unit of the adenylyl cyclase (AC) with age was 
consistently observed [147, 152, 153]. 
In humans and animals, a decrease in the levels of the β1-adrenoceptor and Gs 
protein in the ventricular myocardium appear to be responsible for the reduction in β-
adrenoceptor activity in aging [154]. In contrast, the increase in Gi protein levels and 
the reduction in the activity of the catalytic subunit of the AC lead to attenuated cyclic 
AMP formation in aged right atrial tissue [155]. However, irrespective of the underlying 
mechanism, the responses of the aged human heart to β-adrenoceptor stimulation and to 
stimulation by other receptors (i.e., serotonin 5-HT4 receptors and histamine H2 
receptors) that evoke their effects through activation of AC are impaired. The density of 
muscarinic receptors also decreased with age in the human heart, and there was a 
significant inverse correlation between muscarinic receptor density and the age of the 
subjects. This decrease in receptor density was accompanied by an impairment in 
carbachol-induced inhibition of AC and an attenuation of the indirect negative inotropic 
effect of carbachol with aging [156, 157]. 
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Taken together, it appears that autonomic receptor systems are altered in the 
aging human heart to protect the heart against a pronounced reduction in β-adrenoceptor 
responsiveness. Indeed, β-adrenoceptors and muscarinic receptors are both desensitized 
in parallel, thereby leading to an unaltered in vivo response of β-adrenoceptor 
stimulation. Furthermore, GRKs activity does not change [158] and therefore does not 
contribute to (or exaggerate) β-adrenoceptor desensitization. 
In the vasculature 
Hypertension, orthostatic hypotension, arterial insufficiency, and atherosclerosis 
are common disorders in the elderly, with a significant morbidity and mortality. It is 
generally understood that with advancing age, vascular tone shifts towards 
vasoconstriction and producing a hypertensive state. This shift is related to the 
precipitous decline of vasorelaxation with advanced age, stimulated by activation of 
Gαs-linked receptors (β-adrenergic, prostanglandin E2, adenosine A2, etc). Therefore, 
research has been focused on age-related changes in GPCR function, and specifically on 
the β-adrenergic receptor cascade [159, 160]. 
In vascular smooth muscle cells the generation of the vasodilatory agent, cAMP, 
by AC activation is due to agonist stimulation of GαsPCRs (β-adrenergic, 
prostanglandin-E2, adenosine A2, etc). Activation of PKA by cAMP initiates 
vasorelaxation through different pathways, all of which lead to a lowering of cytosolic 
Ca2+ [161]. During aging, β-adrenoceptor-mediated function and the subsequent 
generation of cAMP in the vasculature declines, leading to impaired vasorelaxation. 
Because cAMP is also an anti-proliferative agent, this age-related decrease may be 
associated with the progress of atherosclerosis. The accepted explanation for the age-
related lack of β-adrenoceptor function is that GRK and β-arrestin expression is 
upregulated, leading to a higher basal phosphorylation and desensitization of the 
 15 
receptors [162, 163]. Numerous studies demonstrate that Gαs may also undergo age-
related changes that impair its coupling to β-adrenoceptor after agonist-binding, 
decreasing the proportion of high affinity receptors [164, 165]. However, the total β-
adrenergic receptor pool [162, 166] and the expression of Gαs in the vasculature 
remains unchanged with age [162, 167-169]. Further studies of the changes in G protein 
function with age in vascular tissue are needed to determine whether changes in Gαs 
function underlie the loss of β-adrenoceptor-mediated vasorelaxation. A recent report 
has identified a novel regulator of G protein signaling (RGS)/GTPase activating protein 
(GAP) that acts on Gαs [170]. One possible explanation for the age-related alterations 
associated with Gαs is that RGS/GAP activity is enhanced in vessels from older 
animals. Under these conditions, agonist exposure would leave β-adrenoceptors in a 
low-affinity state due to their dissociation from Gαs. Thus, Gαs would not stimulate AC 
to produce cAMP, as Gαs signaling would be quenched due to the high GAP activity of 
the RGS/GTPase activating protein. 
Alterations in the membrane content of cholesterol or phospholipid, in the 
phospholipid distribution, in the molecular species of particular phospholipid classes, 
and in the degree of fatty acid saturation have also been reported in hypertensive 
humans [171-173]. Interestingly, alterations in cell membrane lipid levels are associated 
with a reduction in the density of membrane-associated signaling proteins involved in 
the control of blood pressure, such as G proteins and PKC in elderly hypertensive 
subjects [23]. Therefore, it appears that one way to regulate GPCR signaling in the 
elderly would be through nutritional and pharmacologic interventions aiming at 
normalizing the abnormal lipid composition of the plasma membrane. 
The interest in the potential cardiovascular health benefits of dietary MUFAs has 
increased in recent years [174-176]. It has been demonstrated that in hypertensive 
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normocholesterolemic and hypercholesterolemic subjects, high oleic acid intake (i.e. 
olive oil) lowers blood pressure [176]. Moreover, high oleic acid intake also normalizes 
certain alterations in erythrocyte membrane function in hypertensives, such as the 
distribution of the erythrocyte Na(+)-Li+ countertransport [172] and membrane 
cholesterol [177-179]. Normalization of these parameters by olive oil is concomitant 
with a reduction in blood pressure and strongly related to lipoprotein and membrane 
lipid modifications [30, 176, 180, 181]. In addition, oleic acid regulates the activity of 
adrenoceptor, G protein and adenylyl cyclase activities [71], and the GPCR pathway 
involved in the control of blood pressure. 
In elderly hypertensive subjects, long-term olive oil consumption reduces the 
cholesterol/phospholipid ratio in erythrocyte membranes (before olive oil consumption 
0.44 ± 0.00 and after 0.38 ± 0.01, P<0.05), normalizing these values to those of 
normotensives (0.37 ± 0.01). These decreases in the levels of cholesterol in membranes 
after olive oil consumption are associated with increased membrane fluidity [182]. 
Accordingly, a reduction in membrane fluidity (high cholesterol) has been associated 
with the development of hypertension [183] and with an age-related impairment of β-
adrenergic-mediated vasorelaxation and Gαs coupling [22, 164, 184]. Olive oil 
consumption also induces significant changes in the levels of specific fatty acid 
moieties in phospholipids and cholesterol esters (Table 1). In both cases, MUFA levels 
significantly increase in elderly humans after long-term olive oil consumption, mainly 
due to a rise in the proportion of oleic acid (C18:1). This fact was reflected in a 
significant increase of the MUFA:SFA (saturated fatty acid) ratio (from 0.57 to 0.64 in 
the normotensive group and from 0.57 to 0.65 in the hypertensive subjects) and of the 
MUFA:PUFA ratio in membrane phospholipids (from 0.62 to 0.71 in normotensive 
subjects and from 0.57 to 0.73 in hypertensive subjects). In contrast, the PUFA:SFA 
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ratio did not markedly change under these circumstances. These changes induce 
important alterations in membrane lipid structure because oleic acid favors the 
formation of nonlamellar membrane structures in vitro (hexagonal HII phases) [9, 185]. 
The HII-phase propensity is an important physical property of cell membranes, since it 
influences the localization and activity of several membrane-associated proteins (e.g., G 
proteins and PKC) [10, 14, 70, 71]. Both the type and the quantities of free or esterified 
fatty acids and cholesterol influence the membrane fluidity and HII-phase propensity [9]. 
In this context, the normotensive effects of olive oil could originate from the 
modulation of HII-phase propensity (induced by changes in membrane lipids) and its 
influence on the interaction of G proteins and PKC, in addition to or alternative to 
membrane fluidity. Long-term high oleic acid intake significantly reduces the 
membrane levels of Gαi1/2, Gαs, Gβ and PKCα in elderly hypertensive subjects (Fig. 2). 
These effects are accompanied by a reduction in blood pressure (mean systolic and 
diastolic blood pressure values were 162.4 and 81.0 mm Hg, respectively before and 
138.0 and 72.3 mm Hg after olive oil consumption, P<0.05), suggesting that the 
changes observed may in part account for the normotensive effects of olive oil. 
Moreover, these results support the hypothesis that the lower basal levels of membrane-
associated Gαi1/2, Gαo and PKCα previously found in elderly hypertensive subjects [23] 
result from the compensatory adaptation to other changes that induce hypertension, 
rather than to the etiology of this pathology. Oleic acid has been shown to regulate α2-
adrenoceptors and related signaling proteins in 3T3 cells, whereas the chemically 
related analogues had no effect [71]. This effect has been related to the structural 
regulation of the membrane induced by this fatty acid and it could explain the effects 
induced by high olive oil consumption. Moreover, oleic acid derivatives have been 
found to exert a normotensive action in hypertensive animals [186]. 
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Conclusions 
There is currently strong evidence that the function and expression of GPCRs 
and other related signaling proteins are affected by age. Thus, altered GPCR signaling 
may be involved in many important age-related human diseases, either as a consequence 
of alterations suffered by senescent cells or due to its participation in the origin or the 
development of the disease. Furthermore, it has recently been hypothesized that aging 
could be initiated and modified at the plasma membrane, leading to the proposal that the 
membrane might act as a gate which modulates the signals that induce a senescent 
phenotype [12]. Thus, aging may alter the lipid composition and structure of biological 
membranes, which in turn regulate the activity of membrane proteins involved in cell 
signaling and important physiologic functions, such as growth, neurotransmission and 
blood pressure. In this context, small heat shock proteins can act as membrane lipid 
sensors capable of recognizing membrane lipid structures and of modulating them 
[187]. Moreover, the possibility of reversing the senescent phenotype by simply 
restoring the membrane signaling apparatus confirms the significance of membrane in 
the aging [4]. From these results, it might be hypothesized that the age associated 
decline of GPCR signaling could be initiated and modified at the membrane level and 
consequently, one way to restore the effects of this process in elderly humans would be 
to modify membrane lipid composition and structure. In this sense, fats are important in 
human diet and indeed, different types of food lipids have been associated with both 
positive and negative effects on human health. As such, the oleic acid component of 
Mediterranean diets (i.e., olive oil), has been shown to have beneficial effects in 
important human pathologies linked to age, such as hypertension and related 
cardiovascular disorders [30, 32, 176, 180, 181]. 
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Figure Legends 
 
Figure 1. Age-related incidence of cancer. The figure shows an example of the increase 
in the rate of a specific cancer with age (meningioma), representing the usual trend for 
most cancers, and an example of a cancer whose prevalence decreases with age 
(pilocytic astrocytoma). Adapted from Wrensch et al. 2002. 
 
Figure 2. G protein and PKCα concentrations in erythrocyte membranes of elderly 
subjects. The data shown are the mean ± sem of the G protein densities (n=10). CB 
indicates basal values in control (normotensive) subjects; COO, controls after olive oil 
consumption; HB, basal values in hypertensive subjects; HOO, hypertensive subjects 
after long-term olive oil consumption. Panels show the levels of Gαs, Gαi1/2, Gαo, Gβ 
and PKCα. Quantification was performed by image analysis, using standard curves with 
four points (i.e., total protein loaded vs integrated optical density) of different protein 
contents loaded on the same gels as described [23]. Representative immunoblotting 
bands are also shown. About 36 µg of total protein was loaded for all subjects. *P<0.05; 
**P<0.01; ***P<0.001, vs CB; †P<0.01 vs HB. 
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Table 1. Fatty acid composition of phospholipids in erythrocyte membranes 
(mg/100mg) 
 Normotensives Hypertensives 
Fatty acid species Basal Long-term olive 
oil 
Basal Long-term olive 
oil 
14:1 2.21 ± 0.26 2.49 ± 0.16 1.84 ± 0.22 2.62 ± 0.14† 
16:0 22.93 ± 0.45 24.08 ± 0.86 24.00 ± 0.67 25.76 ± 0.49 
16:1 0.81 ± 0.08 0.80 ± 0.07 0.85 ± 0.08 0.93 ± 0.08 
18:0 16.88 ± 0.82 14.56 ± 0.63* 16.42 ± 0.29 13.31 ± 0.68† 
18:1 17.49 ± 0.42 20.00 ± 1.01* 17.90 ± 0.79 19.30 ± 0.93 
18:2 13.25 ± 0.49 12.05 ± 0.60 12.75 ± 0.79 12.43 ± 0.70 
18:3 0.73 ± 0.03 0.42 ± 0.03† 0.68 ± 0.06 0.52 ± 0.05* 
20:2 2.14 ± 0.17 2.35 ± 0.22 2.22 ± 0.14 2.14 ± 0.12 
20:4 16.98 ± 0.44 16.02 ± 0.73 16.81 ± 0.34 15.47 ± 0.62* 
22:5 3.47 ± 0.18 3.30 ± 0.21* 3.28 ± 0.24 2.86 ± 0.12 
Others 3.12 ± 0.12 3.92 ± 0.16 2.40 ± 0.22 3.85 ± 0.32† 
Total SFA 39.99±0.66 38.89±0.89 40.73±0.59 39.3±0.72 
Total MUFA 22.91±0.54 25.36±0.42† 21.42±0.66 25.51±0.47† 
Total PUFA 37.10±0.57 35.73±0.55† 37.85±0.68 35.18±0.72† 
MUFA:SFA 0.57±0.07 0.65±0.06 0.52±0.05 0.65±0.06† 
MUFA:PUFA 0.62±0.05 0.71±0.06* 0.57±0.04 0.72±0.06† 
PUFA:SFA 0.93±0.04 0.92±0.03 0.93±0.03 0.90±0.04 
 
SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, 
polyunsaturated fatty acids. Values are expressed as the mean ± SEM (n=28). *P < 
0.05, †P < 0.01, when compared to the corresponding basal group. 
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